Clinical research
GENFIT announced the launch of a P2 clinical trial evaluating elafibranor’s activity on liver fat quantity and – most importantly – fat composition in nonalcoholic fatty liver disease (NAFLD) patients.
MD Anderson Phase II study suggests patients with lymphoma subtype may be able to avoid chemotherapy in the future
Minoryx Therapeutics announces that the first patient has been dosed with its lead candidate, leriglitazone, in the phase 2 FRAMES clinical trial in Friedreich’s Ataxia.
As the American Society of Clinical Oncology Annual Meeting winds down, here’s a look at some of Monday’s top stories.
Xofluza showed a significant preventive effect after a single oral dose. Only about 1.9% of patients who received Xofluza showed signs of the flu, compared to 13.6% of the placebo group.
Arcutis, Inc. announced that it has enrolled the first patient in a Phase 2a clinical trial evaluating ARQ-151 as a potential treatment for atopic dermatitis (AD).
Nivolumab plus ipilimumab meet primary endpoint of MD Anderson NEOSTAR Phase II trial
The experimental drug enfortumab vedotin, developed by Astellas and Seattle Genetics, demonstrated a 44% objective response rate in patients.
Companies share robust oncology data at annual ASCO meeting.
Overall survival rates in the intent-to-treat population at 42 months for the Kisquali combination group was 70.2% compared to 46.0% for hormone therapy alone.
PRESS RELEASES